Navigation Links
ConfometRx and UCB Announce New R&D Partnership
Date:2/21/2013

PALO ALTO, Calif., Feb. 21, 2013 /PRNewswire-USNewswire/ -- ConfometRx announced today that it has sealed a research agreement with UCB to enable the discovery of novel medicines addressing unmet medical need in Neuroscience. Under this two-year multi-target agreement UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs. GPCRs are the largest family of signaling proteins in the human genome. They are involved in virtually all physiological processes and represent the single largest target class for medicines on the market.  The terms of the agreement, whose details are not disclosed, include an up-front payment, research funding and success-based milestones.

(Logo: http://photos.prnewswire.com/prnh/20120228/DC61335LOGO)

Tong Sun Kobilka , CEO of ConfometRx, said: "We are delighted to be working with UCB's world-class Central Nervous System research group to enhance their drug development activities. With over 20 years of experience working in the coupled receptor field and our unique technological approach, we believe that we can bring significant value to UCB's novel drug development process. We look forward to working closely with UCB's R&D teams."  

Ismail Kola, Executive Vice President and President, NewMedicines at UCB said, "GPCR crystallization remains a challenge and requires state-of-the-art technologies as well as expertise. Professor Brian Kobilka is the first to have succeeded in crystallizing a GPCR target in the active state and was awarded the chemistry Nobel prize for his work in the field of GPCR structural biology. We look forward to working with ConfometRx as part of our continued strategy to innovate in drug discovery, transforming knowledge and insight into health-changing invention. We strive to fulfill our mission of discovering new medicines that aim to improve the lives of people living with severe diseases. The collaboration with ConfometRx is another example of UCB's strategies at work where we are continuing building supernetworks of innovation that are aimed at building superior and sustainable value for patients."

About ConfometRx
ConfometRx, a leader in G protein coupled receptor (GPCR) structural characterization and analysis, has exclusive rights to the patented T4-lysozyme (T4-L) protein fusion stabilization technology used to solve at least thirteen novel GPCR structures.  This pioneering protein fusion technology was developed by Stanford Professor and ConfometRx co-Founder, Dr. Brian Kobilka , and Stanford University has been awarded six separate patents on this fundamental technology with other patents still pending both in the U.S. and abroad.

If you have any questions or would like to learn more about ConfometRx's proprietary technology or to discuss a possible partnering arrangement in the United States or abroad, please contact Dickstein Shapiro LLP, Attn: Deborah Fishman , 1841 Page Mill Road, Suite 150, Palo Alto, CA 94304, phone: (650) 690-9500, fax: (650) 690-9501, e-mail:  fishmand@dicksteinshapiro.com.



'/>"/>
SOURCE ConfometRx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 ... the growing legal cannabis industry is strongly contributing to ... provides comprehensive analysis and reporting for the cannabis industry, ... create more than a quarter million jobs for American ... $7.2 billion in 2016, and is projected to grow ...
(Date:3/22/2017)... March 22, 2017  As the world,s leading non-profit ... Society (LLS) has played a role in most therapies ... which are even helping patients with other cancers and ... significant investment in cutting-edge research – more than $1 ... grow with the record-breaking sum of $4.1 million raised ...
(Date:3/22/2017)... SANTA CLARA, Calif. , March 22, 2017 ... diagnostic cardiology  solutions segment, Frost & Sullivan recognizes ... Sullivan Company of the Year Award. GE Healthcare,s ... offer end-to-end cardiac solutions has allowed it to ... competitive cardiac monitoring products space. In addition to ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... HealthiPASS, Inc., announces ... creating a positive patient experience. , HealthiPASS has further enhanced its predictive ... by helping them understand their financial responsibility. “Our latest release focuses on ...
(Date:3/22/2017)... CA (PRWEB) , ... March 22, 2017 , ... Nearly ... should not undergo PSA (prostate-specific antigen) screening, the cancer screening continues to stir controversy. ... 2008 because it found that the risks outweighed the benefits. Now, news from ...
(Date:3/22/2017)... ... , ... The National Association for Business Resources (NABR) has recently ... in Wellness® companies for 2017. , American Specialty Health (ASH) was honored ... for its employees. ASH is one of only nine other San Diego companies being ...
(Date:3/22/2017)... ... March 22, 2017 , ... Winter ... reduces pigmentation to enhance surgical and nonsurgical procedures—Lytera 2.0 by SkinMedica. Lytera 2.0 ... the face, neck and décolletage in as little as 4 weeks. Skin pigmentation ...
(Date:3/20/2017)... ... ... The topic of healthcare in America has become one of the most ... is that they are still left without the health insurance coverage they need in ... that an unfortunate side-effect of this scenario is that hospital emergency rooms and urgent ...
Breaking Medicine News(10 mins):